The Indirect Impact of COVID-19 Pandemic on Mortality, Complications, and Healthcare Utilization Among Patients With Chronic Respiratory Diseases in Hong Kong: An Interrupted Time Series Analysis

Abstract

Purpose: This study aimed to investigate COVID-19's indirect influence on chronic respiratory disease (CRD) patients for two years since the COVID-19 pandemic began.

Methods: Using population-based data in Hong Kong, we included CRD patients diagnosed from January 2011 to December 2021. Interrupted Time Series Analysis were applied to assess mortality, complications, and healthcare utilization rates during the “pre-COVID-19 pandemic” (January 2012–January 2020), “initial COVID-19 pandemic” (February 2020–February 2021), and “post-initial COVID-19 pandemic” (March 2021–December 2021) periods.

Results: Among 587,049 patients with CRD, all-cause mortality had an increasing trend during the post-initial COVID-19 pandemic period (incidence rate ratio (95% CI): 1.019 (1.005, 1.034); p = 0.007), compared with pre-COVID-19 pandemic period. Nonrespiratory mortality had an increasing trend in the initial COVID-19 pandemic period (1.020 (1.006, 1.033); p = 0.004) and was higher than the pre-pandemic level in the post-initial COVID-19 pandemic. We observed abrupt declines in the incidence rates of asthma exacerbation, acute exacerbation of chronic obstructive pulmonary disease, pneumonia, and acute respiratory failure in the first month of initial COVID-19 pandemic period, remaining below pre-COVID-19 pandemic levels throughout the initial pandemic period.

Conclusion: The disruption of usual healthcare impacts mortality rates among patients with CRD without COVID-19, particularly nonrespiratory mortality. Contingency plans on continuing follow-up and monitoring of CRD patients are needed, for example, teleconsultations, shared primary care, and tele-reminders on red-flag symptoms for patients with CRD, when healthcare services may be disrupted during public health crises.

Keywords

chronic respiratory disease / COVID-19 / healthcare system / mortality

References

[1] GBD 2019 Chronic Respiratory Diseases Collaborators. “Global Burden of Chronic Respiratory Diseases and Risk Factors, 1990-2019: An Update From the Global Burden of Disease Study 2019.” EClinicalMedicine 59, (2023): 101936.

[2] C. Janson, G. Johansson, B. Stallberg, et al., “Identifying the Associated Risks of Pneumonia in COPD Patients: ARCTIC an Observational Study,” Respiratory Research 19, no. 1 (2018): 172.

[3] S. R. Zaidi and J. D. Blakey, “Why Are People With Asthma Susceptible to Pneumonia? A Review of Factors Related to Upper Airway Bacteria,” Respirology (Carlton, Vic.) 24, no. 5 (2019): 423-430.

[4] Global Initiative for Chronic Obstructive Lung Disease (GOLD), Global Strategy for Prevention, Diagnosis and Management of COPD: 2023 Report, https://goldcopd.org/2023-gold-report-2/.

[5] The British Thoracic Society, BTS/SIGN British Guideline on the Management of Asthma, https://www.brit-thoracic.org.uk/quality-improvement/guidelines/asthma/.

[6] M. A. Alsallakh, S. Sivakumaran, S. Kennedy, et al., “Impact of COVID-19 Lockdown on the Incidence and Mortality of Acute Exacerbations of Chronic Obstructive Pulmonary Disease: National Interrupted Time Series Analyses for Scotland and Wales,” BMC Medicine [Electronic Resource] 19, no. 1 (2021): 124.

[7] A. H. Y. Chan, A. Tomlin, E. Chan, J. Harrison, and K. A. Beyene, “Effect of the COVID-19 Pandemic on Asthma Exacerbations in New Zealand: An Interrupted Time Series Analysis,” Journal of Allergy and Clinical Immunology: Global 2, no. 4 (2023): 100157.

[8] M. I. Saeed, P. Sivapalan, J. Eklof, et al., “Social Distancing in Relation to Severe Exacerbations of Chronic Obstructive Pulmonary Disease: A Nationwide Semi-Experimental Study During the COVID-19 Pandemic,” American Journal of Epidemiology 191, no. 5 (2022): 874-885.

[9] I. Sarc, A. Lotric Dolinar, T. Morgan, J. Sambt, K. Ziherl, D. Gavric, et al., “Mortality, Seasonal Variation, and Susceptibility to Acute Exacerbation of COPD in the Pandemic Year: A Nationwide Population Study,” Therapeutic Advances in Respiratory Disease 16 (2022): 17534666221081047.

[10] J. Poucineau, T. Delory, N. Lapidus, et al., “Hospital Admissions and Mortality for Acute Exacerbations of COPD During the COVID-19 Pandemic: A Nationwide Study in France,” Frontiers in Medicine (Lausanne) 9 (2022): 995016.

[11] S. A. Shah, J. K. Quint, B. I. Nwaru, and A. Sheikh, “Impact of COVID-19 National Lockdown on Asthma Exacerbations: Interrupted Time-Series Analysis of English Primary Care Data,” Thorax 76, no. 9 (2021): 860-866.

[12] H. Y. Lam, T. S. Lam, C. H. Wong, et al., “The Epidemiology of COVID-19 Cases and the Successful Containment Strategy in Hong Kong-January to May 2020,” International Journal of Infectious Diseases 98 (2020): 51-58.

[13] T. Burki, “Hong Kong's Fifth COVID-19 Wave—The Worst yet,” The Lancet Infectious Diseases 22, no. 4 (2022): 455-456.

[14] Health Authority, Introduction: Caring for Our Community's Health (Health Authority, 2024).

[15] Statistics Canada, Age-Standardized Rates (Statistics Canada, 2023).

[16] L. L. Chen, S. M. U. Abdullah, W. M. Chan, et al., “Contribution of Low Population Immunity to the Severe Omicron BA.2 Outbreak in Hong Kong,” Nature Communications 13, no. 1 (2022): 3618.

[17] J. M. Ver Hoef and P. L. Boveng, “Quasi-Poisson vs. Negative Binomial Regression: How Should We Model Overdispersed Count Data?,” Ecology 88, no. 11 (2007): 2766-2772.

[18] J. S. T. Zee, C. T. L. Chan, A. C. P. Leung, et al., “Rapid Antigen Test During a COVID-19 Outbreak in a Private Hospital in Hong Kong,” Hong Kong Medical Journal 28, no. 4 (2022): 300-305.

[19] M. Höfler, “Causal Inference Based on Counterfactuals,” BioMed Central Medical Research Methodology 5, no. 1 (2005): 28.

[20] M. E. Charlson, P. Pompei, K. L. Ales, and C. R. MacKenzie, “A New Method of Classifying Prognostic Comorbidity in Longitudinal Studies: Development and Validation,” Journal of Chronic Diseases 40, no. 5 (1987): 373-383.

[21] L. Degli Esposti, V. Perrone, D. Sangiorgi, M. Andretta, F. Bartolini, A. Cavaliere, et al., “The Use of Oral Amino-Bisphosphonates and Coronavirus Disease 2019 (COVID-19) Outcomes,” Journal of Bone and Mineral Research 36, no. 11 (2021): 2177-2183.

[22] B. Giordani, A. Burgio, F. Grippo, A. Barone, E. Eugeni, and G. Baglio, “The Use of ICD-9-CM Coding to Identify COVID-19 Diagnoses and Determine Risk Factors for 30-Day Death Rate in Hospitalized Patients in Italy: Retrospective Study,” Journal of Medical Internet Research Public Health and Surveillance 10 (2024): e44062.

[23] T. Greulich, B. J. D. Weist, A. R. Koczulla, et al., “Prevalence of Comorbidities in COPD Patients by Disease Severity in a German Population,” Respiratory Medicine 132 (2017): 132-138.

[24] M. C. Smith and J. P. Wrobel, “Epidemiology and Clinical Impact of Major Comorbidities in Patients With COPD,” International Journal of Chronic Obstructive Pulmonary Disease 9 (2014): 871-888.

[25] A. S. Gershon, C. Wang, J. Guan, and T. To, “Burden of Comorbidity in Individuals With Asthma,” Thorax 65, no. 7 (2010): 612-618.

[26] P. E. Stevens, S. B. Ahmed, J. J. Carrero, et al., “KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease,” Kidney International 105, no. 4 (2024): S117-S314.

[27] K. Whelton Paul, M. Carey Robert, S. Aronow Wilbert, et al., “2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults,” Journal of the American College of Cardiology 71, no. 19 (2018): e127-e248.

[28] M. E. Czeisler, K. Marynak, K. E. N. Clarke, et al., “Delay or Avoidance of Medical Care Because of COVID-19-Related Concerns—United States, June 2020,” Mmwr Morbidity and Mortality Weekly Report 69, no. 36 (2020): 1250-1257.

[29] S. A. Shah, J. K. Quint, and A. Sheikh, “Impact of COVID-19 Pandemic on Asthma Exacerbations: Retrospective Cohort Study of Over 500,000 Patients in a National English Primary Care Database,” Lancet Regional Health— Europe 19 (2022): 100428.

[30] L. E. Wee, E. P. Conceicao, J. Y. Tan, J. X. Y. Sim, and I. Venkatachalam, “Reduction in Asthma Admissions During the COVID-19 Pandemic: Consequence of Public Health Measures in Singapore,” European Respiratory Journal 57, no. 4 (2021): 2004493.

[31] A. Bourdin, E. Ahmed, I. Vachier, et al., “Hospitalizations for Chronic Obstructive Pulmonary Disease Exacerbation during COVID-19,” JAMA Network Open 7, no. 5 (2024): e2412383.

[32] S. J. Kim, T. Kim, H. Choi, et al., “Respiratory Pathogen and Clinical Features of Hospitalized Patients in Acute Exacerbation of Chronic Obstructive Pulmonary Disease After COVID 19 Pandemic,” Scientific Reports 14, no. 1 (2024): 10462.

[33] A. T. Pavia, “What Is the Role of respiratory Viruses in Community-Acquired Pneumonia?: What Is the Best Therapy for Influenza and Other Viral Causes of Community-acquired Pneumonia?,” Infectious Disease Clinics of North America 27, no. 1 (2013): 157-175.

[34] D. Lieberman, A. Shimoni, Y. Shemer-Avni, A. Keren-Naos, R. Shtainberg, and D. Lieberman, “Respiratory Viruses in Adults With Community-Acquired Pneumonia,” Chest 138, no. 4 (2010): 811-816.

[35] B. J. Cowling, S. T. Ali, T. W. Y. Ng, et al., “Impact Assessment of Non-Pharmaceutical Interventions Against Coronavirus Disease 2019 and Influenza in Hong Kong: An Observational Study,” Lancet Public Health 5, no. 5 (2020): e279-e288.

[36] F. Ahmed, N. Zviedrite, and A. Uzicanin, “Effectiveness of Workplace Social Distancing Measures in Reducing Influenza Transmission: A Systematic Review,” BMC Public Health [Electronic Resource] 18, no. 1 (2018): 518.

[37] M. C. Kim, O. J. Kweon, Y. K. Lim, S. H. Choi, J. W. Chung, and M. K. Lee, “Impact of Social Distancing on the Spread of Common respiratory Viruses During the Coronavirus Disease Outbreak,” PLoS ONE 16, no. 6 (2021): e0252963.

[38] K. F. Chan, T. F. Ma, M. S. Ip, and P. L. Ho, “Invasive Pneumococcal Disease, Pneumococcal Pneumonia and All-Cause Pneumonia in Hong Kong During the COVID-19 Pandemic Compared With the Preceding 5 Years: A Retrospective Observational Study,” British Medical Journal Open 11, no. 10 (2021): e055575.

[39] Y. Farrugia, B. P. Spiteri Meilak, N. Grech, et al., “The Impact of COVID-19 on Hospitalised COPD Exacerbations in Malta,” Pulmonary Medicine 2021 (2021): 5533123.

[40] D. A. R. Albuquerque, M. D. T. Melo, T. L. F. Sousa, P. G. Normando, and J. G. M. Fagundes, “Araujo-Filho JAB. Hospital Admission and Mortality Rates for Non-COVID-19 Respiratory Diseases in Brazil's Public Health System During the Covid-19 Pandemic: A Nationwide Observational Study,” Jornal Brasileiro de Pneumologia 49, no. 1 (2023): e20220093.

[41] A. Dang, R. Thakker, S. Li, E. Hommel, H. B. Mehta, and J. S. Goodwin, “Hospitalizations and Mortality from Non-SARS-CoV-2 Causes Among Medicare Beneficiaries at US Hospitals During the SARS-CoV-2 Pandemic,” JAMA Network Open 5, no. 3 (2022): e221754.

[42] E. Kondilis, F. Tarantilis, and A. Benos, “Essential Public Healthcare Services Utilization and Excess Non-COVID-19 Mortality in Greece,” Public Health 198 (2021): 85-88.

[43] M. Nagamine, D. S. Chow, P. D. Chang, B. Boden-Albala, W. Yu, and J. E. Soun, “Impact of COVID-19 on Acute Stroke Presentation at a Comprehensive Stroke Center,” Frontiers in Neurology 11 (2020): 850.

[44] The Government of the Hong Kong Special Administrative Region, 2021 Population Census. Available from:, https://www.censtatd.gov.hk/en/scode600.html.

[45] W. C. Kwok, T. C. C. Tam, C. W. Sing, E. W. Y. Chan, and C. L. Cheung, “Validation of Diagnostic Coding for Bronchiectasis in an Electronic Health Record System in Hong Kong,” Pharmacoepidemiology and Drug Safety 32, no. 10 (2023): 1077-1082.

[46] W. C. Kwok, T. C. C. Tam, C. W. Sing, E. W. Y. Chan, and C. L. Cheung, “Validation of Diagnostic Coding for Asthma in an Electronic Health Record System in Hong Kong,” Journal of Asthma and Allergy 16 (2023): 315-321.

RIGHTS & PERMISSIONS

2025 The Author(s). Journal of Evidence-Based Medicine published by Chinese Cochrane Center, West China Hospital of Sichuan University and John Wiley & Sons Australia, Ltd.